What is StemSave?
StemSave operates as a global authority in the specialized field of dental stem cell banking. The firm provides a critical service by facilitating the collection and long-term cryopreservation of stem cells derived from deciduous and wisdom teeth. As the sole ASI-approved entity in this niche, StemSave bridges the gap between routine dental procedures and advanced personalized medicine. The company serves a diverse ecosystem of families, dental practitioners, and healthcare professionals, offering a scalable platform for future therapeutic applications in chronic disease management. By transforming biological waste into a high-value health asset, StemSave occupies a unique defensive and growth-oriented position in the biotechnology market.
How much funding has StemSave raised?
StemSave has raised a total of $25K across 1 funding round:
Debt
$25K
Debt (2021): $25K with participation from PPP
Key Investors in StemSave
PPP
Public-Private Partnership
What's next for StemSave?
With the recent infusion of capital, StemSave is expected to prioritize the expansion of its laboratory capabilities and the broadening of its professional network. The strategic focus will likely shift toward increasing market penetration among dental health providers and investing in research initiatives that validate the clinical efficacy of dental-derived stem cells. As the company matures through its Series B/C stage, the emphasis will remain on scaling its storage capacity and refining its digital enrollment platform to meet the rising demand for proactive health management solutions. This phase of development is critical for establishing long-term competitive moats in the regenerative health industry.
See full StemSave company page
